Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001001233-25-000024
Filing Date
2025-11-06
Accepted
2025-11-06 08:07:16
Documents
69
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q sgmo-20250930.htm   iXBRL 10-Q 1110589
2 EX-10.1 sgmo-20250930xex101.htm EX-10.1 27541
3 EX-10.2 sgmo-20250930xex102.htm EX-10.2 41411
4 EX-10.3 sgmo-20250930xex103.htm EX-10.3 41749
5 EX-31.1 sgmo-20250930xex311.htm EX-31.1 9872
6 EX-31.2 sgmo-20250930xex312.htm EX-31.2 9950
7 EX-32.1 sgmo-20250930xex321.htm EX-32.1 7018
  Complete submission text file 0001001233-25-000024.txt   6356917

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20250930.xsd EX-101.SCH 45847
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT sgmo-20250930_cal.xml EX-101.CAL 60580
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sgmo-20250930_def.xml EX-101.DEF 221639
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20250930_lab.xml EX-101.LAB 556361
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20250930_pre.xml EX-101.PRE 409431
72 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20250930_htm.xml XML 809785
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30171 | Film No.: 251456282
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)